Cormorant Asset Management as of Dec. 31, 2023
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 48 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 24.5 | $513M | 8.5M | 60.39 | |
| Ambrx Biopharma | 7.6 | $160M | 11M | 14.24 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 6.7 | $140M | 6.0M | 23.11 | |
| Bridgebio Pharma (BBIO) | 6.4 | $135M | 3.3M | 40.37 | |
| Arcellx Common Stock (ACLX) | 4.5 | $94M | 1.7M | 55.50 | |
| Rayzebio | 3.6 | $75M | 1.2M | 62.17 | |
| Biomea Fusion (BMEA) | 2.5 | $52M | 3.6M | 14.52 | |
| Immunovant (IMVT) | 2.3 | $49M | 1.2M | 42.13 | |
| Alpine Immune Sciences | 2.3 | $49M | 2.6M | 19.06 | |
| Pharvaris N V (PHVS) | 2.3 | $48M | 1.7M | 28.05 | |
| Alx Oncology Hldgs (ALXO) | 2.2 | $47M | 3.1M | 14.89 | |
| Tarsus Pharmaceuticals (TARS) | 2.1 | $45M | 2.2M | 20.25 | |
| Cymabay Therapeutics | 2.0 | $43M | 1.8M | 23.62 | |
| Vaxcyte (PCVX) | 2.0 | $42M | 665k | 62.80 | |
| Crinetics Pharmaceuticals In (CRNX) | 2.0 | $41M | 1.2M | 35.58 | |
| Apellis Pharmaceuticals (APLS) | 1.8 | $37M | 625k | 59.86 | |
| Marinus Pharmaceuticals Com New (MRNS) | 1.7 | $35M | 3.3M | 10.87 | |
| Autolus Therapeutics Spon Ads (AUTL) | 1.7 | $35M | 5.5M | 6.44 | |
| Olema Pharmaceuticals (OLMA) | 1.6 | $35M | 2.5M | 14.03 | |
| Immuneering Corp Class A Com (IMRX) | 1.5 | $31M | 4.2M | 7.35 | |
| Edgewise Therapeutics (EWTX) | 1.3 | $28M | 2.6M | 10.94 | |
| Aerovate Therapeutics (AVTE) | 1.3 | $27M | 1.2M | 22.63 | |
| Cargo Therapeutics (CRGX) | 1.3 | $27M | 1.2M | 23.15 | |
| Syndax Pharmaceuticals (SNDX) | 1.2 | $25M | 1.2M | 21.61 | |
| Korro Bio (KRRO) | 1.2 | $25M | 529k | 47.93 | |
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $25M | 550k | 45.97 | |
| Abivax Sa Sponsored Ads (ABVX) | 1.1 | $23M | 2.1M | 10.70 | |
| Harpoon Therapeutics Com New | 1.1 | $23M | 2.3M | 9.60 | |
| Spyre Therapeutics Com New (SYRE) | 1.0 | $20M | 937k | 21.52 | |
| Insmed Com Par $.01 (INSM) | 0.9 | $18M | 575k | 30.99 | |
| Ideaya Biosciences (IDYA) | 0.8 | $16M | 450k | 35.58 | |
| Axonics Modulation Technolog (AXNX) | 0.7 | $16M | 250k | 62.23 | |
| Neurogene (NGNE) | 0.7 | $15M | 746k | 19.38 | |
| Longboard Pharmaceuticals In (LBPH) | 0.7 | $14M | 2.4M | 6.03 | |
| Praxis Precision Medicines I Com New (PRAX) | 0.7 | $14M | 633k | 22.28 | |
| Rocket Pharmaceuticals (RCKT) | 0.6 | $14M | 450k | 29.97 | |
| Rapt Therapeutics (RAPT) | 0.6 | $12M | 497k | 24.85 | |
| Disc Medicine (IRON) | 0.3 | $7.2M | 125k | 57.76 | |
| Stoke Therapeutics (STOK) | 0.3 | $5.7M | 1.1M | 5.26 | |
| Editas Medicine Put Option (EDIT) | 0.2 | $5.1M | 500k | 10.13 | |
| Verve Therapeutics (VERV) | 0.2 | $4.9M | 350k | 13.94 | |
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.2 | $4.7M | 75k | 62.00 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $4.5M | 562k | 7.96 | |
| Biohaven (BHVN) | 0.2 | $3.5M | 82k | 42.80 | |
| Gh Research Ordinary Shares (GHRS) | 0.2 | $3.4M | 593k | 5.80 | |
| Vyne Therapeutics (VYNE) | 0.2 | $3.2M | 1.4M | 2.33 | |
| Bioatla (BCAB) | 0.1 | $2.9M | 1.2M | 2.46 | |
| Neumora Therapeutics (NMRA) | 0.1 | $1.6M | 92k | 17.05 |
